Crystal structure of the PIM2 kinase in complex with an organoruthenium inhibitor.Bullock, A.N., Russo, S., Amos, A., Pagano, N., Bregman, H., Debreczeni, J.E., Lee, W.H., von Delft, F., Meggers, E., Knapp, S.
(2009) PLoS One 4: e7112-e7112
- PubMed: 19841674
- DOI: https://doi.org/10.1371/journal.pone.0007112
- Primary Citation of Related Structures:
- PubMed Abstract:
The serine/threonine kinase PIM2 is highly expressed in human leukemia and lymphomas and has been shown to positively regulate survival and proliferation of tumor cells. Its diverse ATP site makes PIM2 a promising target for the development of anticancer agents. To date our knowledge of catalytic domain structures of the PIM kinase family is limited to PIM1 which has been extensively studied and which shares about 50% sequence identity with PIM2.
University of Oxford, Structural Genomics Consortium, Oxford, United Kingdom.